CLEO Commences Ovarian Cancer Screening Test Development
Filed with ASX · · 3 pages · English
Summary by 6ix AI
CLEO Diagnostics Ltd has announced the commencement of prototype development for its multi-marker screening blood test aimed at early-stage ovarian cancer detection in asymptomatic women. The company is targeting a significant global market for population screening while continuing to advance its pre-surgical test, which is on track for FDA submission.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CLEO Diagnostics
- CLIA Certified Lab selected - Pivotal US Clinical Validation
- CLEO Receives First Batch of Commercial Test Kits
- Appendix 4E and 2026 Annual Report
- CLEO Enters Analytical Validation Phase
- CLEO Establishes U.S. Reimbursement Pathway
Later from CLEO Diagnostics
- Cleo Files Patents for its Ovarian Cancer Screening Test
- CLEO Commences Analytical Validation Ahead of FDA Submission
- CLEO Screening Test Meets Rigorous Performance Targets
- Quarterly activities and cashflow report
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics